The phase III TroFuse-005 trial evaluating sacituzumab tirumotecan, an investigational TROP2-directed antibody-drug conjugate, met its primary endpoints of overall survival and progression-free survival in certain patients with advanced or recurrent endometrial cancer.
Exploratory analyses of the POTOMAC phase III trial showed adding one year of treatment with AstraZeneca’s Imfinzi (durvalumab) to BCG induction and maintenance therapy reduced the number of high-risk disease recurrences within the first year, with fewer BCG-unresponsive recurrences in patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer compared to BCG treatment alone.
